These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 32884985)

  • 41. Artificial neural network models for early diagnosis of hepatocellular carcinoma using serum levels of α-fetoprotein, α-fetoprotein-L3, des-γ-carboxy prothrombin, and Golgi protein 73.
    Li B; Li B; Guo T; Sun Z; Li X; Li X; Chen L; Zhao J; Mao Y
    Oncotarget; 2017 Oct; 8(46):80521-80530. PubMed ID: 29113322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma.
    Zhan Z; Guan Y; Mew K; Zeng W; Peng M; Hu P; Yang Y; Lu Y; Ren H
    Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G305-G312. PubMed ID: 31736338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.
    El-Mazny A; Sayed M; Sharaf S
    Arab J Gastroenterol; 2014 Jun; 15(2):68-71. PubMed ID: 25097049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fucosylated fraction of alpha-fetoprotein as a serological marker of early hepatocellular carcinoma.
    Moriya S; Morimoto M; Numata K; Nozaki A; Shimoyama Y; Kondo M; Nakano M; Maeda S; Tanaka K
    Anticancer Res; 2013 Mar; 33(3):997-1001. PubMed ID: 23482772
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
    Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
    Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis.
    Thompson Coon J; Rogers G; Hewson P; Wright D; Anderson R; Cramp M; Jackson S; Ryder S; Price A; Stein K
    Health Technol Assess; 2007 Sep; 11(34):1-206. PubMed ID: 17767898
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
    Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
    Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biomarkers for the early diagnosis of hepatocellular carcinoma.
    Tsuchiya N; Sawada Y; Endo I; Saito K; Uemura Y; Nakatsura T
    World J Gastroenterol; 2015 Oct; 21(37):10573-83. PubMed ID: 26457017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HCC biomarkers - state of the old and outlook to future promising biomarkers and their potential in everyday clinical practice.
    Schlosser S; Tümen D; Volz B; Neumeyer K; Egler N; Kunst C; Tews HC; Schmid S; Kandulski A; Müller M; Gülow K
    Front Oncol; 2022; 12():1016952. PubMed ID: 36518320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma.
    Yao M; Zhao J; Lu F
    Oncotarget; 2016 Jan; 7(4):3702-8. PubMed ID: 26784252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma.
    Song T; Li L; Wu S; Liu Y; Guo C; Wang W; Dai L; Zhang T; Wu H; Su B
    Front Oncol; 2021; 11():583714. PubMed ID: 33777736
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of high-sensitivity C-reactive protein tests for the diagnosis of hepatocellular carcinoma in patients with hepatitis B-associated liver cirrhosis.
    Ma LN; Liu XY; Lu ZH; Wu LG; Tang YY; Luo X; Hu YC; Yan TT; Wang Q; Ding XC; Xie Y
    Oncol Lett; 2017 May; 13(5):3457-3464. PubMed ID: 28521452
    [TBL] [Abstract][Full Text] [Related]  

  • 53. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-Related Mortality in Patients With Cirrhosis.
    Moon AM; Weiss NS; Beste LA; Su F; Ho SB; Jin GY; Lowy E; Berry K; Ioannou GN
    Gastroenterology; 2018 Oct; 155(4):1128-1139.e6. PubMed ID: 29981779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Did AFP-L3 save ultrasonography in community screening?
    Yen CW; Kuo YH; Wang JH; Chang KC; Kee KM; Hung SF; Chen Y; Tsai LS; Chen SC; Hung CH; Lu SN
    Kaohsiung J Med Sci; 2018 Oct; 34(10):583-587. PubMed ID: 30309487
    [TBL] [Abstract][Full Text] [Related]  

  • 55. TEMs but not DKK1 could serve as complementary biomarkers for AFP in diagnosing AFP-negative hepatocellular carcinoma.
    Mao L; Wang Y; Wang D; Han G; Fu S; Wang J
    PLoS One; 2017; 12(9):e0183880. PubMed ID: 28902891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches.
    Zhu J; Warner E; Parikh ND; Lubman DM
    Mass Spectrom Rev; 2019 May; 38(3):265-290. PubMed ID: 30472795
    [TBL] [Abstract][Full Text] [Related]  

  • 57. C-reactive protein is a biomarker of AFP-negative HBV-related hepatocellular carcinoma.
    She S; Xiang Y; Yang M; Ding X; Liu X; Ma L; Liu Q; Liu B; Lu Z; Li S; Liu Y; Ran X; Xu X; Hu H; Hu P; Zhang D; Ren H; Yang Y
    Int J Oncol; 2015 Aug; 47(2):543-54. PubMed ID: 26058824
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development and potential application of a simultaneous multiplex assay of Golgi protein 73 and alpha-fetoprotein for hepatocellular carcinoma diagnosis.
    Xiao J; Long F; Peng T; Hu LB; Cai H; Chen R; Chen WL
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3302-3310. PubMed ID: 31081083
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hepatitis B- and hepatitis C-associated hepatocellular carcinoma: evaluation of alpha-fetoprotein as a diagnostic marker.
    Songsivilai S; Dharakul T; Senawong S
    Asian Pac J Allergy Immunol; 1995 Dec; 13(2):167-71. PubMed ID: 8703246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Application of surveillance programs for hepatocellular carcinoma in the Asia-Pacific Region.
    Amarapurkar D; Han KH; Chan HL; Ueno Y;
    J Gastroenterol Hepatol; 2009 Jun; 24(6):955-61. PubMed ID: 19383082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.